全文获取类型
收费全文 | 27221篇 |
免费 | 1724篇 |
国内免费 | 92篇 |
专业分类
耳鼻咽喉 | 452篇 |
儿科学 | 1340篇 |
妇产科学 | 809篇 |
基础医学 | 3514篇 |
口腔科学 | 500篇 |
临床医学 | 2482篇 |
内科学 | 5201篇 |
皮肤病学 | 691篇 |
神经病学 | 2272篇 |
特种医学 | 813篇 |
外科学 | 3820篇 |
综合类 | 912篇 |
现状与发展 | 1篇 |
一般理论 | 29篇 |
预防医学 | 2235篇 |
眼科学 | 710篇 |
药学 | 1721篇 |
1篇 | |
中国医学 | 53篇 |
肿瘤学 | 1481篇 |
出版年
2022年 | 249篇 |
2021年 | 404篇 |
2020年 | 236篇 |
2019年 | 363篇 |
2018年 | 440篇 |
2017年 | 313篇 |
2016年 | 393篇 |
2015年 | 469篇 |
2014年 | 572篇 |
2013年 | 917篇 |
2012年 | 1258篇 |
2011年 | 1202篇 |
2010年 | 778篇 |
2009年 | 780篇 |
2008年 | 1104篇 |
2007年 | 1113篇 |
2006年 | 1034篇 |
2005年 | 1076篇 |
2004年 | 1042篇 |
2003年 | 971篇 |
2002年 | 889篇 |
2001年 | 384篇 |
2000年 | 371篇 |
1999年 | 389篇 |
1998年 | 366篇 |
1997年 | 345篇 |
1996年 | 370篇 |
1995年 | 326篇 |
1994年 | 279篇 |
1993年 | 306篇 |
1992年 | 328篇 |
1991年 | 314篇 |
1990年 | 327篇 |
1989年 | 335篇 |
1988年 | 298篇 |
1987年 | 287篇 |
1986年 | 276篇 |
1985年 | 275篇 |
1984年 | 232篇 |
1983年 | 185篇 |
1982年 | 197篇 |
1981年 | 208篇 |
1980年 | 170篇 |
1959年 | 352篇 |
1958年 | 765篇 |
1957年 | 873篇 |
1956年 | 778篇 |
1955年 | 809篇 |
1954年 | 787篇 |
1949年 | 187篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
L. TIMMER-DE MIK M.D. D.M. BROEKHUIJSEN-VAN HENTEN M.D. † J.M. OLDHOFF M.D. PH.D. D.B. DE GEER M.D. ‡ V. SIGURDSSON M.D. PH.D. S.G.M.A. PASMANS M.D. PH.D. 《Pediatric dermatology》2009,26(3):358-360
Abstract: In Sweet's syndrome, the essential features are the characteristic morphology of the lesions, their histologic appearance, the dramatic response to corticosteroids and the absence of scarring. We report an 8-month-old infant in whom Sweet's syndrome was diagnosed and who developed acquired cutis laxa in the skin lesions. 相似文献
22.
23.
24.
25.
Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years 总被引:2,自引:0,他引:2
Christopher J. E. Watson J. Andrew Bradley Peter J. Friend John Firth Craig J. Taylor John R. Bradley Kenneth G. C. Smith Sathia Thiru Neville V. Jamieson Geoff Hale Herman Waldmann Roy Calne 《American journal of transplantation》2005,5(6):1347-1353
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. In the alemtuzumab group 12% of recipients died compared to 17% in the control group (p = 0.48); likewise graft loss was similar in both groups (21% vs. 26%, respectively, p = 0.58). Incidence of acute rejection was also comparable at 5 years (31.5% vs. 33.6%), although the pattern of rejection was different with 14% patients in the alemtuzumab group experiencing rejection over 1 year post-transplant compared to none in the control group. There was no significant difference between groups in terms of infection or serious adverse events. While acknowledging the limitations of a relatively small single-center study, results suggest that alemtuzumab induction allowed satisfactory long-term patient and graft survival equivalent to that seen with standard triple immunosuppression, while avoiding steroid therapy. 相似文献
26.
F. Hampton Roy MD 《Annals of Ophthalmology》2006,38(1):35-38
A red eye is a cardinal sign of ocular inflammation. Most cases are benign and can be managed by the primary care provider.
The key is recognizing cases requiring ophthalmological consultation by differentiating between ciliary and conjunctival injection.
Ciliary injection indicates inflammation of the cornea, iris, or ciliary body, whereas conjunctival injection mainly affects
the posterior conjunctival blood vessels.
The author has stated that he does not have a significant financial interest or other relationship with any product manufacturer
or provider of services discussed in this article. The author also does not discuss the use of off-label products, which includes
unlabeled, unapproved, or investigative products or devices. 相似文献
27.
28.
29.
30.